Juvenile Idiopathic Arthritis

Gowdie, Peter; Tse, Shirley M. L.

doi:10.1016/j.pcl.2012.03.014

Cited by 107 publications

(106 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has a prevalence of up to 4 in 1,000 children (1). JIA is classified into categories according to the International League of Associations for Rheumatology classification criteria (2).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry

Foeldvari

Becker

Horneff

2015

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveUveitis is a major extraarticular quality of life–restricting manifestation of juvenile idiopathic arthritis (JIA). The aim of the study is to describe the occurrence of uveitis in JIA patients receiving tumor necrosis factor inhibitors or methotrexate (MTX).MethodsPatients’ characteristics, treatment, and the reported first occurrence of uveitis as an adverse event were searched in the Biologics in Pediatric Rheumatology Registry. The rates per exposed patients, exposure time, and time until event were calculated.ResultsUveitis was reported as an adverse event in 75 of 3,467 patients; 51 of 2,844 patients were receiving MTX, 37 of 1,700 patients were receiving etanercept, and 13 of 364 patients were receiving adalimumab. Patients with uveitis were younger (mean ± SD age 4.6 ± 4.2 versus 7.4 ± 4.5 years; P < 0.0001), more likely to be antinuclear antibody positive (69% versus 43%; odds ratio [OR] 2.7, P < 0.0001), and had extended oligoarticular JIA (OR 2.2, P = 0.0005). Patients with a uveitis diagnosis before starting treatment more often had a uveitis event (n = 28, 8.4%; OR 8.5, P < 0.0001), and more often received adalimumab (OR 2.15 [95% confidence interval 1.58–2.94], P < 0.0001). In 16 patients, a new uveitis event occurred: 11 while taking MTX (3.2 per 1,000 patient‐years), 2 while taking etanercept monotherapy (1.9 per 1,000 patient‐years), and 3 while taking etanercept and MTX combination (0.9 per 1,000 patient‐years). A new uveitis event occurred early in the disease course after a median disease duration of 1.5 years (interquartile range [IQR] 1.3–3.8) while taking etanercept and 1.8 years (IQR 1.8–2.1) for the MTX cohort. A recurrent uveitis event was reported after a disease duration of 7.6 years (IQR 4.3–10.0) in the etanercept cohort and 4.8 years (IQR 1.0–5.8) in the MTX cohort. Univariate analysis showed that MTX, but not etanercept or adalimumab, led to a lower rate of uveitis.ConclusionPatients with a history of uveitis had higher risks for uveitis events while taking both etanercept and adalimumab. Methotrexate turned out to be protective. Few patients developed a first uveitis event while taking etanercept, while the rate is comparable to that with MTX. Uveitis may not be attributed to be an adverse drug reaction to etanercept.

show abstract

“…It has a prevalence of up to 4 in 1,000 children (1). JIA is classified into categories according to the International League of Associations for Rheumatology classification criteria (2).…”

Section: Introductionmentioning

confidence: 99%

“…1 the eye, affecting mostly the iris and ciliary body. It is usually insidious in onset, and is initially almost always asymptomatic.…”

Section: Introductionmentioning

confidence: 99%

Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry

Foeldvari

Becker

Horneff

2015

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…It is not recommended to be used in systemic JIA, since the risk of side effects is increased. The initial dose is 10-20 mg/kg/day and the dose is increased to 30-50 mg/kg/day in weeks (1)(2)(3)(11)(12)(13)(14).…”

Section: Non-biological Drugs Used In Treatment Of Juvenile Idiopathimentioning

confidence: 99%

“…TNF-alpha is responsible of synovitis and inflammatory events, IL-1 is responsible of joint destruction and IL-6 is responsible of systemic finsings including fever and rash. Production of biological drugs against these cytokines gained speed especially after the second half of the 1990s (1)(2)(3)14). This drug group is used more widely in adults and their safety has been proven.…”

Section: Biological Drugsmentioning

confidence: 99%